个人简介
1994年获武汉大学医学院医学学士学位, 2002年获新加坡国立大学博士学位,2003-2007年在新国大和美国约翰霍普金斯大学从事博士后研究。长期从事肿瘤分子病理学及医学转化研究,发表SCI研究论文近100篇,论文他引总数超过4000次,H-index=42。工作以来在Nat Commun,Cell Res., PNAS, Cancer Res., Small等杂志上共发表通讯作者论文40余篇。
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
1. Zhang W, Wu M, Kang Y, Chong QY, Zhang M, Qian W, Zhang X, Hu L, Zhong Y, Qian P, Kong X, Li G, Ding K, LobiePE*, Zhu T*(2018)Loss of Estrogen Regulated MIR135A1 at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer Cells. Cancer Res. 78(17):4915-4928
2. Tan S, Li H, Zhang W, Shao Y, Liu Y, Guan H, WU J, Kang Y, Zhao J, Yu Q, Gu Y, Ding K, Zhang M, Qian W, Zhu Y, Cai H, Chen C, LobiePE, Zhao X*, Sun J* Zhu T*(2018) NUDT21 Negatively Regulates PSMB2 and CXXC5 by Alternative Polyadenylation and Contributes to Hepatocellular Carcinoma Suppression. Oncogene 37(35):4887-4900
3. Li G, Wu X, Qian W, Wu ZS, Cai H, Sun X, Zhang W, Tan S, Qian P, Ding K, Lu X, Zhang X, Yan H, Song H, Huang S, Wu Q, Lobie PE, Shan G, Zhu T (2016) CCAR1 5'UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance. Cell Res 26:655-73
4. Liu Y, Qian P, Chen C, Lu X, Sun B, Zhang X, Wang L, Gao X, Li H, Chen Z, Tang J, Zhang W, Dong J, Bai R, Lobie PE, Wu Q, Liu S, Zhang H, Zhao F, Wicha MS, Zhu T*, Zhao Y*. (2015) Gd-metallofullerenol nanomaterial nanomaterial as non-toxic cancer stem cell specific inhibitor. Nat Commun. 6,5988
5. Lu X, Liu Y, Kong X, Lobie PE, Chen C*, Zhu T*. (2013) Nanotoxicity: A growing need for study in the endocrine system. Small 9,1654-71
学术兼职
担任Am J. Cancer Res.等多家国际期刊资深编委或编委及数家海外科研基金评审。